Schuepke, S. and Neumann, F. -J and Menichelli, M. and Mayer, K. and Bernlochner, I. and Woehrle, J. and Richardt, G. and Liebetrau, C. and Witzenbichler, B. and Antoniucci, D. and Akin, I. and Bott-Fluegel, L. and Fischer, M. and Landmesser, U. and Katus, H. A. and Sibbing, D. and Seyfarth, M. and Janisch, M. and Boncompagni, D. and Hilz, R. and Rottbauer, W. and Okrojek, R. and Moellmann, H. and Hochholzer, W. and Migliorini, A. and Cassese, S. and Mollo, P. and Xhepa, E. and Kufner, S. and Strehle, A. and Leggewie, S. and Allali, A. and Ndrepepa, G. and Schuehlen, H. and Angiolillo, D. J. and Hamm, C. W. and Hapfelmeier, A. and Toelg, R. and Trenk, D. and Schunkert, H. and Laugwitz, K. -L and Kastrati, A. (2019) Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes. NEW ENGLAND JOURNAL OF MEDICINE, 381 (16). pp. 1524-1534. ISSN 0028-4793, 1533-4406
Full text not available from this repository. (Request a copy)Abstract
Background The relative merits of ticagrelor as compared with prasugrel in patients with acute coronary syndromes for whom invasive evaluation is planned are uncertain. Methods In this multicenter, randomized, open-label trial, we randomly assigned patients who presented with acute coronary syndromes and for whom invasive evaluation was planned to receive either ticagrelor or prasugrel. The primary end point was the composite of death, myocardial infarction, or stroke at 1 year. A major secondary end point (the safety end point) was bleeding. Results A total of 4018 patients underwent randomization. A primary end-point event occurred in 184 of 2012 patients (9.3%) in the ticagrelor group and in 137 of 2006 patients (6.9%) in the prasugrel group (hazard ratio, 1.36; 95% confidence interval [CI], 1.09 to 1.70; P=0.006). The respective incidences of the individual components of the primary end point in the ticagrelor group and the prasugrel group were as follows: death, 4.5% and 3.7%; myocardial infarction, 4.8% and 3.0%; and stroke, 1.1% and 1.0%. Definite or probable stent thrombosis occurred in 1.3% of patients assigned to ticagrelor and 1.0% of patients assigned to prasugrel, and definite stent thrombosis occurred in 1.1% and 0.6%, respectively. Major bleeding (as defined by the Bleeding Academic Research Consortium scale) was observed in 5.4% of patients in the ticagrelor group and in 4.8% of patients in the prasugrel group (hazard ratio, 1.12; 95% CI, 0.83 to 1.51; P=0.46). Conclusions Among patients who presented with acute coronary syndromes with or without ST-segment elevation, the incidence of death, myocardial infarction, or stroke was significantly lower among those who received prasugrel than among those who received ticagrelor, and the incidence of major bleeding was not significantly different between the two groups.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | MYOCARDIAL-INFARCTION; CLOPIDOGREL; OUTCOMES; TRIALS; |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Innere Medizin II |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 25 Mar 2020 09:16 |
| Last Modified: | 25 Mar 2020 09:16 |
| URI: | https://pred.uni-regensburg.de/id/eprint/25992 |
Actions (login required)
 |
View Item |
